Neurofibromatosis Treatment Market Report 2026

The neurofibromatosis treatment market size has grown rapidly in recent years. It will grow from $14.83 billion in 2025 to $16.7 billion in 2026 at a compound annual growth rate (CAGR) of 12.6%. The growth in the historic period can be attributed to rising diagnosis of neurofibromatosis disorders, early adoption of surgical tumor removal, development of radiation therapy methods, increased awareness of genetic disorders, initial growth of targeted therapy options.

The neurofibromatosis treatment market size is expected to see rapid growth in the next few years. It will grow to $27.75 billion in 2030 at a compound annual growth rate (CAGR) of 13.5%. The growth in the forecast period can be attributed to growing demand for precision oncology treatments, increasing availability of genetic testing tools, rising investment in tumor-targeting drug development, expansion of minimally invasive surgical options, development of novel pain management solutions. Major trends in the forecast period include increasing use of targeted drug therapy for tumor reduction, rising adoption of surgical treatment for complication management, growing demand for radiation therapy in nf2 cases, expansion of genetic counseling and early detection programs, increasing focus on pain management and symptom control.

The increasing research and development (R&D) activities are expected to drive the growth of the neurofibromatosis treatment market in the coming years. R&D activities involve systematic, goal-oriented efforts aimed at generating new knowledge, developing innovative technologies, and advancing products or services through scientific investigation and technical experimentation. A key factor boosting these activities is the growing demand for more effective, targeted medical solutions, which encourages organizations to invest in novel scientific approaches that address unmet clinical needs and improve long-term health outcomes. In this context, advancements in neurofibromatosis treatment highlight the importance of ongoing innovation in complex disease areas and motivate further exploration of therapeutic breakthroughs. For example, in April 2025, the Office for National Statistics, a UK-based statistics authority, reported that the UK government’s net R&D expenditure rose to £17.4 billion ($21.8 billion) in 2023 from £16.1 billion ($20.1 billion) in 2022, representing an 8.2% increase. Therefore, the rising R&D activities are propelling the growth of the neurofibromatosis treatment market.

Major companies in the neurofibromatosis treatment market are focusing on developing innovative drugs and investigational targeted therapies, such as MEK inhibitors, to maintain a competitive edge. MEK inhibitors are a class of targeted therapies that block the MEK enzyme, part of the MAPK signaling pathway, to treat cancers and genetic disorders like neurofibromatosis by inhibiting cell growth and tumor progression. For instance, in March 2024, SpringWorks Therapeutics, Inc., a US-based biopharmaceutical company, completed its submission of a new drug application to the FDA for Mirdametinib, aimed at treating both children and adults with NF1-PN. Mirdametinib is a selective MEK inhibitor designed to target specific pathways involved in neurofibroma growth. The FDA’s review will assess the safety and efficacy of this treatment, with the potential to significantly improve outcomes for individuals affected by NF1-PN.

In July 2025, Merck KGaA, a Germany-based science and technology company, acquired SpringWorks Therapeutics for $3.4 billion. Through this acquisition, Merck KGaA aims to expand its rare tumor portfolio and strengthen its global oncology strategy by incorporating SpringWorks’ FDA-approved therapies for desmoid tumors and neurofibromatosis type 1-related plexiform neurofibromas. SpringWorks Therapeutics is a US-based provider of targeted therapies for rare tumors and genetically defined cancers, including approved treatments for desmoid tumors and NF1-associated plexiform neurofibromas.

Major companies operating in the neurofibromatosis treatment market are Pfizer Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., Novartis AG, Sanofi S.A., AstraZeneca plc, GSK PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Vertex Pharmaceuticals Inc., BioMarin Pharmaceutical, BioXcel Therapeutics Inc., Blueprint Medicines Corp., SpringWorks Therapeutics, Affymax Inc., NFlection Therapeutics Inc., Mulberry Biotherapeutics, CureAge Therapeutics, Recursion Pharmaceuticals, Vivace Therapeutics, Healx Limited, NF2 Therapeutics Inc.

North America was the largest region in the neurofibromatosis treatment market in 2025. The regions covered in the neurofibromatosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neurofibromatosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the neurofibromatosis treatment market by increasing the costs of imported oncology drugs, diagnostic kits, and radiation therapy equipment required to manage tumor growth and related symptoms. These tariffs most significantly affect hospitals and specialty clinics in regions reliant on imported pharmaceuticals such as Europe and Asia-Pacific, resulting in higher treatment expenses and longer procurement timelines. Treatment categories including targeted therapy, radiation therapy, and surgical equipment face increased operational burdens. However, tariffs are encouraging local manufacturing, enhancing regional supply chains, and promoting innovation in more accessible and affordable treatment options.

The neurofibromatosis treatment market research report is one of a series of new reports that provides neurofibromatosis treatment market statistics, including neurofibromatosis treatment industry global market size, regional shares, competitors with a neurofibromatosis treatment market share, detailed neurofibromatosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the neurofibromatosis treatment industry. This neurofibromatosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neurofibromatosis treatment involves managing a genetic disorder that leads to tumor growth on nerve tissue, which can occur anywhere in the body, including the brain, spinal cord, and nerves. This treatment aims to manage symptoms, slow disease progression, and prevent potential complications.

Neurofibromatosis treatment is applied for neurofibromatosis 1 (NF1), neurofibromatosis 2 (NF2), and schwannomatosis. Neurofibromatosis type 1 (NF1) is a genetic condition marked by the formation of tumors on nerves throughout the body. Treatment options include medications, surgery, radiation therapy, and other approaches, with hospitals, clinics, and similar healthcare facilities serving as the primary end-users.

The neurofibromatosis treatment market consists of revenues earned by entities by providing services such as stereotactic radiosurgery, genetic evaluation, physical therapy and rehabilitation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurofibromatosis treatment market also includes sales of drugs such as selumetinib, bevacizumab and tricyclic antidepressants. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.